We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Collegium Pharmaceutical Inc (COLL) USD0.001

Sell:$26.21 Buy:$36.96 Change: $1.20 (3.56%)
Market closed |  Prices as at close on 17 May 2024 | Switch to live prices |
Change: $1.20 (3.56%)
Market closed |  Prices as at close on 17 May 2024 | Switch to live prices |
Change: $1.20 (3.56%)
Market closed |  Prices as at close on 17 May 2024 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Collegium Pharmaceutical, Inc. is a diversified specialty pharmaceutical company. The Company commercializes its pain portfolio, consisting of Xtampza extended-release (ER), Nucynta ER and Nucynta immediate-release (IR), Belbuca, and Symproic in the United States. Xtampza ER is an abuse-deterrent, extended-release, oral formulation of oxycodone. Xtampza ER is a pain treatment option designed with abuse deterrent properties and uses a technology platform, DETERx. The Nucynta Products are ER and IR oral formulations of tapentadol. Nucynta ER is indicated for the management of severe and persistent pain that requires an extended treatment period with a daily opioid analgesic. Nucynta IR is indicated for the management of acute pain severe enough to require an opioid analgesic. Belbuca is a buccal film that contains buprenorphine for severe and persistent pain. Symproic is used for the treatment of opioid-induced constipation (OIC) in adult patients with chronic non-cancer pain.

Contact details

100 Technology Center Dr
United States
+1 (781) 7133699

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
$1.11 billion
Shares in issue:
32.72 million
United States
US dollar
NASDAQ Comb. Composite

Key personnel

  • Michael Heffernan
    Independent Chairman of the Board
  • Joseph Ciaffoni
    President, Chief Executive Officer, Director
  • Colleen Tupper
    Chief Financial Officer, Executive Vice President
  • Shirley Kuhlmann
    Executive Vice President, Chief Administrative Officer, General Counsel, Secretary
  • Scott Dreyer
    Executive Vice President, Chief Commercial Officer
  • Thomas Smith
    Executive Vice President, Chief Medical Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.